免疫腫瘍学のための二重特異性抗体の開発とメカニスティック・モデルに基づいた探索:It takes 2 to tango
More than 50 bispecific antibodies are in oncology clinical development with a large diversity in formats, directed at a range of immune and tumor targets. Bispecifics have demonstrated the potential for enhanced efficacy and reduced systemic toxicity. However, they are complex modalities with challenges to overcome in early clinical trials, including selection of relevant starting … Continued